Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives

Urinary tumors primarily consist of kidney, urothelial, and prostate malignancies, which pose significant treatment challenges, particularly in advanced stages. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach, combining monoclonal antibody specificity with cytotoxic...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 13; p. 1259784
Main Authors Li, Keqiang, Xie, Guoqing, Deng, Xiyue, Zhang, Yu, Jia, Zhankui, Huang, Zhenlin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 20.12.2023
Subjects
ADC
bladder
kidney
Oncology
prostate
urinary tumors
urothelial cancer
ADC
kidney
prostate
urothelial cancer
urinary tumors
bladder
Online AccessGet full text

Cover

More Information
Summary:Urinary tumors primarily consist of kidney, urothelial, and prostate malignancies, which pose significant treatment challenges, particularly in advanced stages. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach, combining monoclonal antibody specificity with cytotoxic chemotherapeutic payloads. This review highlights recent advancements, opportunities, and challenges in ADC application for urinary tumors. We discuss the FDA-approved ADCs and other novel ADCs under investigation, emphasizing their potential to improve patient outcomes. Furthermore, we explore strategies to address challenges, such as toxicity management, predictive biomarker identification, and resistance mechanisms. Additionally, we examine the integration of ADCs with other treatment modalities, including immune checkpoint inhibitors, targeted therapies, and radiation therapy. By addressing these challenges and exploring innovative approaches, the development of ADCs may significantly enhance therapeutic options and outcomes for patients with advanced urinary tumor.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Ronald M. Bukowski, Cleveland Clinic, United States
Reviewed by: Shawn C. Owen, The University of Utah, United States
These authors have contributed equally to this work and share first authorship
Jean-Marc Barret, GamaMabs Pharma, France
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1259784